FDA Biosim Interchangeability Guidance is Befuddling
Continuing our deep dive into biosimilars It may well take the wisdom of Solomon to fully appreciate the logic of the recently released guidance (or
November 21, 2023
Continuing our deep dive into biosimilars It may well take the wisdom of Solomon to fully appreciate the logic of the recently released guidance (or
Continuing our focus on Biosimilars The FDA recently approved a new infused biosimilar, Tofidence (tocilizumab-bavi) from Biogen, for the treatment of moderately to severely active
Continuing Biosimilar Week Recently the FDA approved a new biosimilar, Tyruko (natalizumab-sztn) from Sandoz Inc., with indications for adults with relapsing forms of multiple sclerosis,
We are going to hear a lot more about biosimilars in coming days. The leader board now shows that 44 biosimilars have been approved to date…. even
Ok….. here’s something innovative in the wacky world of specialty pharmacy! CVS has launched a new subsidiary called Cordavis. The new entity “will work directly with
The article below was published some weeks ago, but its insight is very timely. It is a simple story….. one in which the Pharma industry is
Catching up on recent FDA approvals. The FDA recently approved a new oral therapy, Sohonos (palovarotene) from Ipsen Biopharmaceuticals, for reduction in the volume of
Catching up on recent approvals…….. The FDA recently approved a new oral therapy, Akeega (niraparib and abiraterone acetate) from Janssen Pharmaceutical, the first-and-only dual action
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
It’s ALIVE!!! Artificial Intelligence is here. The article below details how HCSC, which covers about 18 million members in Illinois, Montana, New Mexico, Oklahoma and Texas,
